Molecular basis for the relationship between thrombosis and cancer

Thrombosis Research

Volumn 102, Issue 6, 2001, Pages

  Rickles, Frederick R ^a   Falanga, Anna ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Angiogenesis; Cancer; Cytokines; Fibrinolysis; Procoagulants; Thromboembolism

Indexed keywords

BINDING PROTEIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; CANCER PROCOAGULANT; INTERLEUKIN 1BETA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; BLOOD CLOTTING; CANCER; CANCER INHIBITION; CANCER PATIENT; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; IMMUNE RESPONSE; MACROPHAGE; METASTASIS; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOEMBOLISM;

EID: 0035876016     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00285-7     Document Type: Article

References (63)

1. Activation of blood coagulation in cancer: Trousseau's syndrome revisited
2. Cancer and thrombosis: From phlegmasia alba dolens to transgenic mice
3. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia
4. The management of bleeding and thrombosis in leukemia
5. Phlegmasia alba dolens
6. Venous thromboembolism in malignancy and malignancy in venous thromboembolism
7. Abnormalities of hemostasis in malignancy
8. Hemostatic alterations in cancer patients
9. Thrombosis and cancer
10. Treatment of venous thromboembolism in cancer patients
11. Prevention of venous thromboembolism
12. Antithrombotic strategies in patients with cancer
13. Tumor cell generation of thrombin via prothrombinase assembly
14. Tissue transglutaminase expression in human breast cancer
15. Tissue factor activity in leukemia cells: Special reference to disseminated intravascular coagulation
16. The tissue factor pathway of blood coagulation
17. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice
18. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
19. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein
20. Identification of tissue factor in embryonic blood vessel development
21. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and VEGF in human cancers
22. In situ detection of the expression of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease
23. Fibrin activation of vascular endothelial cells: Induction of IL-8 expression
24. Fibrin induction of tissue factor expression in human vascular endothelial cells
25. The site of activation of factor X by cancer procoagulant
26. Three stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant
27. Comparison of procoagulant activities in extracts of normal and malignant human tissue
28. Cancer procoagulant in human tumor cells: Evidence from melanoma patients
29. Procoagulant activity of human stomach and colon cancers
30. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as new tumor marker
31. Analysis of serum cancer procoagulant activity its possible use as a tumor marker
32. A new procoagulant in acute leukemia
33. Cancer procoagulant in acute lymphoblastic leukemia
34. Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity
35. All-trans retinoic acid (ATRA) inhibits the expression of tissue factor in human progranulocytic leukemia cells
36. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid
37. Tissue factor expression in human leukemic cells
38. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-Retinoic Acid
39. All-trans-Retinoic Acid upregulates thrombomodulin and downregulates tissue factor expression in acute promyelocytic leukemia cells distinct expression of thrombomodulin and tissue factor in human leukemic cells
40. Effect of all-trans-Retinoic Acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia
41. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia cells
42. All-trans-Retinoic Acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4)
43. Inhibitory effects of retinoids on the generation of procoagulant activity by blood mononuclear phagocytes
44. Fibrinolysis and cancer
45. Production of an active urokinase by leukemia cells a novel distinction from cell lines of solid tumors
46. Cellular receptors in the regulation of plasmin generation
47. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia
48. The effect of dexamethasone on proinflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukemia cells
49. Cultured human endothelial cells generate tissue factor in response to endotoxin
50. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin-1
51. Structure and function of thrombomodulin: A natural anticoagulant
52. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
53. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor
54. Progress of fibrinolysis during tumor necrosis factor infusion in humans. Concomitant increase of tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products
55. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia
56. Vascular permeability factor, fibrin, anf the pathogenesis of tumor stroma formation
57. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenesis factor
58. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
59. Molecular mechanisms linking thrombosis and angiogenesis in cancer
60. Pathophysiology of the thrombophilic state in the cancer patient
61. Hypercoagulability in cancer
62. Mechanisms of hypercoagulation in malignancy and during chemotherapy